Edition:
United Kingdom

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

1.55USD
15 Dec 2017
Change (% chg)

$0.06 (+4.03%)
Prev Close
$1.49
Open
$1.48
Day's High
$1.57
Day's Low
$1.48
Volume
25,850
Avg. Vol
68,115
52-wk High
$16.96
52-wk Low
$1.21

Chart for

About

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and... (more)

Overall

Beta: 2.64
Market Cap(Mil.): $18.00
Shares Outstanding(Mil.): 10.91
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura

* ANTHERA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA

11 Dec 2017

BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock

* Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ Source text: (http://bit.ly/2mmbjHr) Further company coverage:

13 Nov 2017

BRIEF-ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58

* ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS

06 Nov 2017

BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma

* Armistice Capital, Llc reports 5.6 percent passive stake in Anthera Pharmaceuticals Inc as on October 24, 2017 - SEC filing‍​ Source text: (http://bit.ly/2A4C2Kr) Further company coverage:

03 Nov 2017

BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering

* Anthera Pharmaceuticals announces pricing of $15 million private placement offering

24 Oct 2017

BRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

* Anthera Pharmaceuticals surpasses 50% milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

07 Sep 2017

BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

* Anthera announces top line final data from the extension period of the phase 2 bright-sc study of blisibimod in patients with IgA nephropathy

28 Aug 2017

BRIEF-Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

* Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

14 Aug 2017

BRIEF-FDA grants orphan status to Anthera's kidney disease drug

* Anthera announces FDA orphan drug designation for blisibimod for the treatment of iga nephropathy

09 Aug 2017

BRIEF-Anthera Pharmaceuticals reports Q2 earnings per share $0.03

* Anthera Pharmaceuticals provides business update and reports 2017 second quarter financial results

09 Aug 2017

Earnings vs. Estimates